Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.

Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.

Graft-versus-host disease (GVHD) is a major cause of mortality and morbidity after allogeneic bone marrow transplantation, but can be avoided by removing T lymphocytes from the donor bone marrow. However, T-cell depletion increases the risk of graft rejection. This study examined the use of CD52 mon...

Descripció completa

Dades bibliogràfiques
Autors principals:	Hale, G, Zhang, M, Bunjes, D, Prentice, H, Spence, D, Horowitz, M, Barrett, A, Waldmann, H
Format:	Journal article
Idioma:	English
Publicat:	1998

Ítems similars

CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
per: Hale, G, et al.
Publicat: (2000)

Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo.
per: Cobbold, S, et al.
Publicat: (1986)

Effect of graft perfusion with two CD45 monoclonal antibodies on incidence of kidney allograft rejection.
per: Brewer, Y, et al.
Publicat: (1989)

In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation.
per: Willemze, R, et al.
Publicat: (1992)

Autografting with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia.
per: Treleaven, J, et al.
Publicat: (1996)

Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation.
per: Heit, W, et al.
Publicat: (1986)

Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia.
per: Singhal, S, et al.
Publicat: (1996)

Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance.
per: Cobbold, S, et al.
Publicat: (1986)

CAMPATH-1 FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT-REJECTION - SUMMARY OF RESULTS FROM A MULTI-CENTRE STUDY
per: Hale, G, et al.
Publicat: (1988)

Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
per: Gupta, V, et al.
Publicat: (2004)

Favourable impact on acute and chronic graft-versus-host disease with cyclophosphamide and in-vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anaemia.
per: Gupta, V, et al.
Publicat: (2004)

Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
per: Hale, G, et al.
Publicat: (1994)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
per: Hale, G, et al.
Publicat: (1996)

Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect.
per: Novitzky, N, et al.
Publicat: (1999)

The repopulation capacity of bone marrow grafts following pretreatment with monoclonal antibodies against T lymphocytes in rhesus monkeys.
per: Gerritsen, W, et al.
Publicat: (1988)

The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
per: Byrne, J, et al.
Publicat: (2000)

T-cell depletion of bone marrow grafts with Campath 1 ex vivo prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation
per: Novitzky, N, et al.
Publicat: (1997)

Ex vivo T-cell depletion of bone marrow grafts with campath 1 prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation.
per: Novitzky, N, et al.
Publicat: (1997)

In vivo/ex vivo T-cell depletion with anti-CD52 monoclonal antibodies: long-term results in patients with acute leukaemia in CR1
per: Bunjes, D, et al.
Publicat: (2004)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
per: Hale, G, et al.
Publicat: (1994)

Antilymphocytic antibodies and marrow transplantation. VII. Two of nine monoclonal anti-Thy-1 antibodies used for pretreatment of donor marrow suppressed graft-versus-host reactions without added complement.
per: Thierfelder, S, et al.
Publicat: (1985)

New approaches for the prevention of rejection and graft-vs.-host disease in clinical bone marrow transplantation.
per: Slavin, S, et al.
Publicat: (1986)

What can be done to prevent graft versus host disease?
per: Waldmann, H, et al.
Publicat: (1994)

Immunosuppression with monoclonal antibodies: some speculations about tolerance in the context of tissue grafting.
per: Waldmann, H
Publicat: (1988)

MONOCLONAL-ANTIBODIES CAN BE USED TO CONTROL BOTH GVHD AND REJECTION IN MOUSE MODELS OF BONE-MARROW TRANSPLANTATION
per: Cobbold, S, et al.
Publicat: (1985)

CD4 T cells can reject major histocompatibility complex class I-incompatible skin grafts.
per: Wise, M, et al.
Publicat: (1999)

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H.
per: Newman, D, et al.
Publicat: (1995)

Prevention of bone marrow graft failure by an anti LFA-1 monoclonal antibody
per: A. Fischer, et al.
Publicat: (1987-01-01)

MONOCLONAL-ANTIBODIES FOR CONDITIONING PRIOR TO MARROW TRANSPLANTATION
per: Hale, G, et al.
Publicat: (1989)

Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1).
per: Waldmann, H, et al.
Publicat: (1984)

A role for Th2 cytokines in the suppression of CD8+ T cell-mediated graft rejection.
per: Scully, R, et al.
Publicat: (1997)

Monoclonals and marrow transplants.
per: Waldmann, H, et al.
Publicat: (1986)

Long-term outcome after marrow transplantation from HLA-identical sibling donors for acquired aplastic anaemia using cyclophosphamide and in-vivo anti-CD52 monoclonal antibodies
per: Gupta, V, et al.
Publicat: (2005)

Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
per: Waldmann, H, et al.
Publicat: (1985)

RAT MONOCLONAL-ANTIBODIES FOR BONE-MARROW TRANSPLANTATION (BMT) - THE CAMPATH SERIES
per: Waldmann, H, et al.
Publicat: (1985)

Cultured keratinocyte grafts are recognized, but not rejected by CD8+ T cells in vivo.
per: Tinois, E, et al.
Publicat: (1989)

Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
per: Friend, P, et al.
Publicat: (1991)

Linked suppression of skin graft rejection can operate through indirect recognition.
per: Wise, M, et al.
Publicat: (1998)

HAPLOIDENTICAL BONE-MARROW TRANSPLANTATION - INVIVO CONDITIONING WITH MONOCLONAL-ANTIBODIES
per: Fasth, A, et al.
Publicat: (1988)

Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.
per: Rebello, P, et al.
Publicat: (1999)